Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Diarrhea 1Colitis 1Breast Neoplasms 1

Interventions

Specimen Handling 147pembrolizumab 124Magnetic Resonance Spectroscopy 114Cyclophosphamide 114Biopsy 104fludarabine 84Nivolumab 59Carboplatin 54Gemcitabine 46Cisplatin 46venetoclax 45Radiotherapy 45Paclitaxel 43Ipilimumab 38fludarabine phosphate 37Cetuximab 37Fluorouracil 34atezolizumab 31Bevacizumab 31durvalumab 30X-Rays 28Oxaliplatin 28Dexamethasone 28Leucovorin 27Radiation 26Irinotecan 26Azacitidine 25Injections 24Cytarabine 24Radiosurgery 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Loperamide × 90 days × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡